share_log

Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target

Benzinga ·  Sep 17 22:37  · Ratings

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $64 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment